Virax Biolabs announced encouraging early pilot data for ViraxImmune™, a blood test in development to detect Long COVID, ME/CFS, and related post-acute infection syndromes. The test showed 88% specificity and 92% positive predictive value in distinguishing patients from healthy controls, supporting further clinical validation. Virax plans a larger study with 300 additional participants starting Q4 2026, aiming for U.S. market entry via a Laboratory Developed Test. If successful, ViraxImmune™ could offer an objective diagnostic tool in an area with significant unmet medical need.
Esperion Therapeutics presented new data at the 2026 European Atherosclerosis Society Congress showing bempedoic acid effectively lowers LDL cholesterol in children aged 6-17 with familial hypercholesterolemia and is well tolerated. A secondary analy...
Auditoria.AI introduced Governed Autonomy, a new framework allowing AI agents to operate within enterprise-defined policies in finance, reducing the need for human approval on every transaction. This shift addresses governance challenges in AI deploy...
Rhythm Pharmaceuticals announced that its CEO and CFO will participate in fireside chats at the Jefferies Global Healthcare Conference on June 4 and the Goldman Sachs Global Healthcare Conference on June 8, 2026. These events will be webcast and acce...
Rani Therapeutics Holdings, a clinical-stage biotherapeutics company, announced a registered direct offering of Class A common stock priced at-the-market under Nasdaq rules. The offering includes 12.48 million shares and pre-funded warrants for 6.21 ...
Microchip Technology has introduced new 3.3 kV HV-D3 mSiC power modules designed to enhance solid-state transformers (SSTs) for AI hyperscale data centers. These modules integrate silicon carbide MOSFETs and Schottky diodes to improve power delivery ...
